HD-OPM Archive
Topics › Plaque, CAC & CT angiography

YELLOW trials: intensive rosuvastatin cut lipid-core plaque within 7-8 weeks

Louis Nervegna · Aug 15, 2026 · ♥ 16 reactions · 19 comments · original Facebook post
Plaque, CAC & CT angiographyStatinsPCSK9, ezetimibe & newer drugs
AI summary & key facts

The YELLOW study found that short-term intensive lipid lowering with rosuvastatin reduced lipid-core burden (yellow plaque) in coronary lesions in as little as 7-8 weeks, stabilizing vulnerable plaque rather than shrinking blockages. YELLOW III added the PCSK9 inhibitor evolocumab to statins with greater improvement in plaque composition. Generic rosuvastatin costs under $10/month.

Cheap generic rosuvastatin reversed unstable soft plaque in just 8 weeks. Cost was < $10/month.

“For the first time, we had proof that the body could start healing its own heart almost immediately.”

“Your arteries are dynamic. They are living tissue that can respond to treatment with incredible speed.”

The YELLOW (Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy) study showed that short-term, intensive lipid-lowering therapy with statins (rosuvastatin) can significantly reduce the lipid-core burden ("yellow plaque") inside coronary artery lesions compared to standard care.

Key Findings of the YELLOW Study

Fast Reduction: Intensive treatment (such as high-dose rosuvastatin) decreased lipid-core content in as little to 7 to 8 weeks.

Plaque Stabilization: Rather than total structural reversal or bulk shrinkage of hard blockages overnight, the treatment made vulnerable, lipid-rich plaques safer and more stable.

Advanced Imaging: The trial used near-infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS) to accurately measure changes inside the artery walls.

Follow-up Studies (YELLOW II and III)

Subsequent trials like YELLOW III evaluated adding PCSK9 inhibitors (like evolocumab) to statin therapy, showing even greater plaque composition improvements and reduction in overall lipid volume in non-obstructive lesions.

#yellowHD #yellowiiHD #yelowiiiHD #reverseHD #statinreverseHD #pcsk9reverseHD #nirsHD #ivusHD #plaqueHD #lipidcoreHD

Research cited

← newer: Group guidelines for AI fact-checking: share the prompt and older: High protein intake not linked to kidney function decline in →